Sugi Predict

Sugi Predict / Compounds / SCHEMBL4336679

SCHEMBL4336679

SCHEMBL4336679

Cc1cccc(CN2CCN(c3cc(F)c(/C=N/NC(N)=S)cc3F)CC2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.45
▸ ALDH1A1 P00352 8/20 0.45
▸ MAPT P10636 4/20 0.45
▸ GAA P10253 2/20 0.45
▸ ALOX12 P18054 2/20 0.45
▸ POLB P06746 1/20 0.43
▸ CASP3 P42574 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ SENP7 Q9BQF6 1/20 0.43
▸ SENP6 Q9GZR1 1/20 0.43
▸ TYR P14679 1/20 0.43
▸ KDM4E B2RXH2 3/20 0.42
▸ HTT P42858 2/20 0.42
▸ PHGDH O43175 1/20 0.42
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ MAOB P27338 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ USP2 O75604 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ CYP3A4 P08684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4336683 1.00 LMNA (0.45) LMNAALDH1A1MAPTGAAALOX12
SCHEMBL4336263 0.90 MAOB (0.47) ALDH1A1GAAPOLBCASP3RAB9A
SCHEMBL4336270 0.90 MAOB (0.47) ALDH1A1GAAPOLBCASP3RAB9A
SCHEMBL4322284 0.90 ALDH1A1 (0.48) LMNAALDH1A1MAPTALOX12POLB
SCHEMBL4322300 0.90 ALDH1A1 (0.48) LMNAALDH1A1MAPTALOX12POLB
SCHEMBL4330305 0.89 POLB (0.52) LMNAALDH1A1MAPTGAAALOX12
SCHEMBL4330311 0.89 POLB (0.52) LMNAALDH1A1MAPTGAAALOX12
SCHEMBL4325307 0.89 L3MBTL1 (0.52) LMNAALDH1A1GAAALOX12POLB
SCHEMBL4325311 0.89 L3MBTL1 (0.52) LMNAALDH1A1GAAALOX12POLB
SCHEMBL4331055 0.86 L3MBTL1 (0.48) LMNAALDH1A1GAAALOX12POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 — — US disclosed
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 — — US disclosed
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 — — US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 — — US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 — — US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 LMNA 4884/4885ALDH1A1 1459/4885MAPT 3619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.